Tirzepatide Shortage Update: What Changed and What It Means for Prices

The tirzepatide shortage has been one of the biggest drivers of pricing changes, compounded demand and patient anxiety since Mounjaro first hit the market. This page traces the shortage from its origins through October 2026, explains what the supply situation looks like now, and covers how the shortage reshaped the pricing landscape that patients navigate today.

The Tirzepatide Shortage: A Brief History

Understanding the current supply picture requires knowing how we got here. The timeline below covers the major events from Mounjaro's launch through the present.

The shortage was not a single event. It unfolded in stages as demand consistently outpaced Eli Lilly's ability to manufacture enough product. Off-label prescribing for weight loss before Zepbound's approval created a demand spike that Lilly's original capacity projections had not anticipated. When Zepbound launched in late 2023, it added a second brand drawing from the same manufacturing pipeline, stretching supply further.

Current Supply Status in October 2026

Supply conditions have shifted significantly since the worst of the shortage, but the picture is not uniform across all dose strengths and formulations.

Mounjaro Availability

Mounjaro availability has improved as Lilly's production expansion came online through 2025 and into 2026. Retail pharmacy stock for the diabetes indication has been more consistent than at any point since the shortage began. That said, individual pharmacies in high-demand areas may still experience intermittent stock-outs at specific dose strengths. For the most current status, check the FDA Drug Shortage Database, which tracks availability by product and manufacturer. We cannot confirm whether Mounjaro is fully off the shortage list as of this writing.

Zepbound Availability

Zepbound supply has followed a similar trajectory. The single-dose vial program through LillyDirect has maintained relatively steady availability since its introduction, partly because the vial format is simpler to manufacture than KwikPens. Pen availability has been more variable. Patients using the LillyDirect self-pay program ($299 to $449 with the 45-day refill window; October 2026) have generally reported fewer fulfillment delays than those filling through retail pharmacies. Again, check the FDA Drug Shortage Database for the latest official status rather than relying on anecdotal reports.

How the Shortage Affected Prices

The shortage did not just limit access. It fundamentally reshaped the pricing landscape for tirzepatide in ways that persist even as supply improves.

Compounded Tirzepatide Demand Surge

When patients could not fill brand-name prescriptions, many turned to compounded alternatives. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies can prepare medications from bulk active ingredient when certain conditions are met, including during periods of drug shortage. The FDA exercised enforcement discretion that allowed compounding of tirzepatide to expand rapidly. Providers like BiltRx ($129 per month, biltrx.com, verified 22 Oct 2026) and Arc-1 ($199.99 to $399.99, arc-1.co, verified 22 Oct 2026) built their patient bases during this window. Our compounded tirzepatide price comparison covers the full cost breakdown.

The compounded market created something that did not exist before the shortage: a sustained low-cost alternative to brand-name tirzepatide. Even as brand-name supply recovers, many patients who started on compounded tirzepatide at $129 per month have little financial incentive to switch to Zepbound at $299 or more.

Manufacturer Price Adjustments

Lilly responded to the competitive pressure from compounding pharmacies with pricing moves that would have been unlikely without the shortage. The Zepbound single-dose vial program through LillyDirect brought FDA-approved tirzepatide to $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 through 15 mg with the 45-day refill window (LillyDirect, October 2026). The Mounjaro self-pay flat rate of $499 at any dose was another concession to affordability. These prices remain well above compounded alternatives but represent a significant discount from the $1,086 (Zepbound WAC) and $1,112 (Mounjaro WAC) list prices. Whether Lilly would have made these moves without the compounding market applying downward price pressure is an open question.

What to Expect Next

Lilly Production Expansion

Eli Lilly has invested billions in manufacturing capacity for tirzepatide and other incretin-class drugs. New facilities and production lines that began coming online in late 2025 are expected to continue ramping through 2026 and beyond. If production meets demand across all dose strengths and formulations, the shortage will formally resolve. That resolution could happen gradually, with some presentations clearing the shortage list before others. Pen devices, which require more complex manufacturing than vials, may be the last to achieve consistent supply.

FDA Guidance on Compounding Post-Shortage

The future of compounded tirzepatide hinges partly on regulatory decisions. The FDA has issued guidance on how it approaches compounding of drugs that are on versus off the shortage list. When a drug exits the shortage list, the regulatory basis for compounding it under certain enforcement discretion frameworks may narrow. However, 503A pharmacies can still compound medications based on individual patient prescriptions under established federal and state law, subject to various requirements. The regulatory situation is evolving, and patients using compounded tirzepatide should stay informed about FDA announcements that could affect availability.

For patients currently on compounded tirzepatide, this uncertainty is worth monitoring but is not a reason to panic. Any regulatory changes would likely come with transition periods. Our cheapest tirzepatide ranking tracks all available options so you can compare alternatives if the compounded landscape shifts.